Despite what the trading activity suggests today (including all the price manipulation, day trading and the like), and all the noise on here, what the reimbursement announcement today means for me is further de-risking of the business. Putting in place the necessary foundations and infrastructure for uptake and success.
Reimbursement is difficult to achieve, even after FDA clearance. And we've achieved that for two products 6 months apart. Reimbursable to over 66 million Americans.
It indicates a strong team of people / advisors who can navigate the reimbursement system strategically and successfully -- with likely oversight from our Board member Geraldine McGinty who's an expert in this area.
With such reimbursement expertise, next cab off the rank is private health insurer reimbursement (of which there are many major providers they can target), and they've been working on this over the past half year... who knows when such news might drop?
They also noted this (USD650) serves as a guide for how much to charge the VA for CT LVAS scans. Much more than the past agreed amount.
Lastly, today's CT LVAS reimbursement success is very timely ahead of the all important ATS 2024 next week/weekend! We can let everyone know that since the last ATS, we've achieved reimbursement for two products and have expanded our portfolio immensely with FDA approved lung structure and heart AI products through Imbio.
(20min delay)